ISSN 1006-298X      CN 32-1425/R

导航

肾脏病与透析肾移植杂志 ›› 2025, Vol. 34 ›› Issue (6): 555-559.DOI: 10.3969/j.issn.1006⁃298X.2025.06.008

• 论著 • 上一篇    下一篇

艾滋病患者血液透析的临床特征

  

  • 出版日期:2025-12-28 发布日期:2025-12-29

Clinical characteristics of acquired immunodeficiency syndrome patients undergoing hemodialysis

  • Online:2025-12-28 Published:2025-12-29

摘要: 目的:探讨艾滋病患者血液透析(HD)后的临床特征,分析免疫功能、人类免疫缺陷病毒(HIV)病毒载量变化、合并症及治疗方案等对疾病的影响。方法:回顾性队列研究,选取 2017 年 8 月至 2021 年 12 月于成都市公共卫生临床医疗中心接受 HD 治疗的艾滋病合并终末期肾病(ESKD)患者 87 例。观察患者免疫功能指标(CD4+T 淋巴细胞计数、CD8 + 淋巴细胞计数、CD4/CD8 比值)、病毒载量、合并症和用药情况。结果:87 例患者中男性 68 例(78.16%);平均年龄 53.38±13.44 岁(23~82 岁)。ESKD 病因以 HIV 相关肾病为主(43.68%)。常见合并症包括肾性贫血(81.61%)、高血压(74.71%)等。主要抗 HIV 方案为阿巴卡韦 + 拉米夫定 + 克力芝(25.29%)、拉米夫定 + 克力芝(20.69%)等。治疗后患者 CD4+T 淋巴细胞计数显著上升(F=8.42,P=0.0005),CD8+T 淋巴细胞计数显著下降(F=19.67,P=0.0001),CD4/CD8 比值显著上升(F=6.23,P=0.0008),HIV 病毒载量显著降低(χ²=156.23,P<0.001)。结论:艾滋病合并 ESKD 的患者 HD 后免疫功能部分改善,病毒载量显著下降,但仍存在免疫功能缺陷。

关键词: font-family:Inter, -apple-system, BlinkMacSystemFont, ", font-size:16px, background-color:#FFFFFF, ">艾滋病、终末期肾病、临床特征、血液透析

Abstract: Objective: To explore the clinical characteristics of acquired immunodeficiency syndrome (AIDS) patients after hemodialysis (HD), and analyze the impacts of immune function, changes in human immunodeficiency virus (HIV) viral load, comorbidities, treatment regimens and other factors on the disease. Methodology: A retrospective cohort study was conducted. A total of 87 AIDS patients complicated with end-stage kidney disease (ESKD) who received HD treatment at Chengdu Public Health Clinical Center from August 2017 to December 2021 were enrolled. The immune function indicators of the patients, including CD4+T lymphocyte count, CD8+T lymphocyte count and CD4/CD8 ratio, as well as HIV viral load, comorbidities and medication status were observed. Results: Among the 87 patients, 68 were male (78.16%), with a mean age of 53.38±13.44 years (range:23-82 years). The primary cause of ESKD was HIV-associated nephropathy (43.68%). Common comorbidities included renal anemia (81.61%) and hypertension (74.71%). The main anti-HIV regimens were abacavir+lamivudine+lopinavir/ritonavir (25.29%) and lamivudine+lopinavir/ritonavir (20.69%). After HD treatment, the patients’ CD4+T lymphocyte count increased significantly (F=8.42, P=0.0005), the CD8+T lymphocyte count decreased significantly (F=19.67, P=0.0001), the CD4/CD8 ratio increased significantly (F=6.23, P=0.0008), and the HIV viral load decreased significantly (χ²=156.23, P<0.001). Conclusion: For AIDS patients with ESKD, their immune function was partially improved and the viral load was significantly reduced after HD, yet immunodeficiency still existed.

Key words: font-family:Inter, -apple-system, BlinkMacSystemFont, ", font-size:16px, background-color:#FFFFFF, ">acquired immunodeficiency syndrome, end-stage kidney disease, clinical characteristics, hemodialysis